gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · HOWLHealthcarePharmaceuticals

Werewolf Therapeutics, Inc. Common Stock (HOWL)

$1.09+1.87%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.09▼ 9.92% in range
Nov 4, 2025Low $0.31 · High $1.22Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Werewolf Therapeutics closed at $1.09 on Nov 4, up 1.87%, 16.8% below its 52-week closing high. Volume of 302.7K shares was 0.73× its 20-day average (below normal).

Split-adjusted performance: +18.5% over one month, +67.6% over six months, -16.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $21M, with a net margin of 17.5%.

Short interest was 2.4M shares at the Oct 15 settlement, down 6.2% from the prior report (5.9% of float, 5.1 days to cover).

Market cap$53.0M48.6M shares
Revenue · quarter$21.0M—
Diluted EPS$0.08—
P/E · TTM—P/S 2.5×
Net margin17.5%Gross 100.0%
Dividend yieldNone
52-week range0.31 – 1.31−16.8% from high
Volume302.7K0.73× 20-day avg
Volatility · 60d152.4%Annualised
Short % of float5.9%5.1 days to cover
Net cash$22.0MCash $22.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +2.8%1M +18.5%3M +170.6%6M +67.6%YTD +72.1%1Y −16.8%3Y −56.7%5Y −92.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum96
Revenue growth—
Net margin85
Value (low P/E)—
Size31

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.4M−6.2% vs prior
Days to cover5.1Settled Oct 15
% of float5.9%
Short vol. 10d42.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
HOWLWerewolf Therapeutics$1.09+1.87%+67.6%—17.5%—$53.0M
PLRXPliant Therapeutics$0.8518−1.03%−30.7%———$52.7MCompare
OSTXOS Therapies Incorporated$1.15−0.86%−33.5%———$53.8MCompare
ANVSAnnovis Bio$1.21+11.01%−49.6%———$51.6MCompare
TLPHTalphera$1.05+0.96%+20.7%———$54.5MCompare
IBIOiBio$0.8000−2.85%−54.8%−100.0%——$51.4MCompare
BOLDBoundless Bio$2.40+0.84%+51.9%———$55.5MCompare
ONCYOncolytics Biotech$0.4248+8.92%−53.8%———$55.7MCompare
RFLRafael Holdings$1.07−0.93%−14.4%−30.3%−3760.7%—$55.8MCompare

News about Werewolf Therapeutics

All news →
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's WhyZacks Investment Research · Oct 13, 2026▲ PositiveBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)GlobeNewswire Inc. · Sep 3, 2026▼ NegativeWerewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate UpdatesGlobeNewswire Inc. · Mar 27, 2026▼ Negative

Quick answers

What does Werewolf Therapeutics do?
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies.
What is HOWL's market cap?
$52.98M, based on the Nov 4 close of $1.09.
Does Werewolf Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of HOWL is sold short?
2.4M shares, 5.9% of float, as of Oct 15, 2026.
What sector is HOWL in?
Healthcare, in the Pharmaceuticals industry.

About Werewolf Therapeutics

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

HQ: Watertown, MA14 employeesListed Apr 30, 2021werewolftx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology